4D Molecular Therapeutics (NASDAQ:FDMT) reported quarterly losses of $(1.01) per share which missed the analyst consensus estimate of $(0.99) by 2.02 percent. This is a 17.44 percent decrease over losses of $(0.86) per share from the same period last year. The company reported quarterly sales of $3.047 million which missed the analyst consensus estimate of $5.167 million by 41.03 percent. This is a 21.66K percent increase over sales of $14.000 thousand the same period last year.